Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0UQXWB
ADC Name
BI-CON-02
Synonyms
BI-CON-02; BI CON 02; BICON02
   Click to Show/Hide
Organization
BioIntegrator LLC
Drug Status
Phase 1 (Terminated)
Indication
In total 1 Indication(s)
Breast cancer
Phase 1
Clinical Trial
Drug-to-Antibody Ratio
Undisclosed
Antibody Name
Trastuzumab
  Antibody Info 
Antigen Name
Receptor tyrosine-protein kinase erbB-2 (HER2)
  Antigen Info 
Payload Name
Undisclosed
Linker Name
Undisclosed
Conjugate Type
Undisclosed
General Information of The Activity Data Related to This ADC
Identified from the Human Clinical Data
Click To Hide/Show 1 Activity Data Related to This Level
Standard Type NCT Number Clinical Status Clinical Trial Description
Undisclosed  NCT03062007
Phase 1
Open-label study of safety, tolerability and pharmacokinetics of multiple doses of BI-CON-02 in patients with HER2-positive metastatic breast cancer, previously treated with trastuzumab.
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Related Clinical Trial
NCT Number NCT03062007  Clinical Status Phase 1
Clinical Description Open-label study of safety, tolerability and pharmacokinetics of multiple doses of BI-CON-02 in patients with HER2-positive metastatic breast cancer, previously treated with trastuzumab.
References
Ref 1 A phase I study of TRS005: An anti-CD20-MMAE antibody-drug conjugate, in relapsed or refractory b cell non-Hodgkin lymphoma. Ann. Oncol. 2022 Sept; 33(7):Supplement S827.